The Hindu·2 min read·medium
Lupin takes 82.2% stake in Kaveri Therapeutics, licences 2 oncology assets for $1.6mn
T
The Hindu Bureau
✦AI Summary
Lupin has acquired an 82.2% stake in Kaveri Therapeutics by licensing two of its oncology programs for $1.6 million. The new company will focus on clinical development for various solid tumor cancers.
Global pharma major Lupin has spun-out two oncology programmes to Kaveri Therapeutics Inc for $1..6 million, taking its stake in the U.S. clinical-stage oncology company to 82.2%.
businesssciencehealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in